[go: up one dir, main page]

PE20000415A1 - Compuestos calciliticos - Google Patents

Compuestos calciliticos

Info

Publication number
PE20000415A1
PE20000415A1 PE1999000275A PE00027599A PE20000415A1 PE 20000415 A1 PE20000415 A1 PE 20000415A1 PE 1999000275 A PE1999000275 A PE 1999000275A PE 00027599 A PE00027599 A PE 00027599A PE 20000415 A1 PE20000415 A1 PE 20000415A1
Authority
PE
Peru
Prior art keywords
alkylene
link
alkyl
aryl
riv
Prior art date
Application number
PE1999000275A
Other languages
English (en)
Inventor
Pradip Kumar Bhatnagar
James Francis Callahan
Mar Eric G Del
Maria Amparo Lago
Thomas The Nguyen
Raul Rolando Calvo
Joelle Lorraine Burgess
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Publication of PE20000415A1 publication Critical patent/PE20000415A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/33—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/60—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/37—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by etherified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA I, DONDE Y1 ES UN ENLACE, ALQUILENO, ALQUENILENO; Y2 ES METILENO; Y3 ES UN ENLACE, O, S, N-RIV, (ALQUILENO C1-C4)-O, (ALQUILENO C1-C4)-S, (ALQUILENO C1-C4)-N-RIV; R3 Y R4 SON METILO O ETILO O JUNTOS FORMAN CICLOPROPILO; R5 ES ARILO, ARILO FUSIONADO, DIHIDRO-, TETRAHIDRO-ARILO FUSIONADO, OPCIONALMENTE SUSTITUIDO ENTRE OTROS; RIV ES H, ALQUILO C1-C4, CICLOALQUILO C3-C6, G ES UN ENLACE, CHR6, C-R6; R6 ES H, OH, O; R7 ES H, OH, O-ALQUILO C1-C4; R8 ES H, ALQUILO C1-C4; O R7 Y R8 FORMAN UNA CETONA; A Y B SON UN ENLACE, CH2, NH, O, S, C=O; A o B FORMAN UN ENLACE; A-B ES CH=CH, C­C; X1 Y X5 SON H, HALOGENO, CN, NO2, ALQUILO C1-C4, CICLOALQUILO, CH2-ARILO, CH2-HETEROARILO; X1 o X5 ES H; X2, X3 Y X4 SON H, HALOGENO, O-ALQUILO C1-C4, O-ARILO, J-K, ENTRE OTROS; J ES UN ENLACE, ALQUILENO, O-ALQUILENO, ALQUENILENO C2-C5; K ES CO2RIV, OH, CN. UN COMPUESTO PREFERIDO ES (R)-N-[2-HIDROXI-3-(2-CIANO-4-(2-CARBOETOXIETIL)FENOXI)PROPIL]-1,1-DIMETIL-2-(2-NAFTIL)ETILAMINA, ENTRE OTROS. EL COMPUESTO I (CALCILITICO) ES UN ANTAGONISTA DEL RECEPTOR DE CALCIO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE UNA ANORMAL HOMEOSTASIS OSEA O MINERAL, OSTEOSARCOMA, ENFERMEDAD PERIODONTAL, CURACION DE FRACTURAS, OSTEOARTRITIS, ARTRITIS REUMATOIDE, ENFERMEDAD DE PAGET, HIPERCALCEMIA HUMORAL, OSTEOPOROSIS
PE1999000275A 1998-04-08 1999-04-06 Compuestos calciliticos PE20000415A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8109398P 1998-04-08 1998-04-08

Publications (1)

Publication Number Publication Date
PE20000415A1 true PE20000415A1 (es) 2000-05-21

Family

ID=22162059

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000275A PE20000415A1 (es) 1998-04-08 1999-04-06 Compuestos calciliticos

Country Status (33)

Country Link
US (1) US6395919B1 (es)
EP (1) EP1070048B1 (es)
JP (1) JP2002510671A (es)
KR (1) KR20010042526A (es)
CN (1) CN1304401A (es)
AP (1) AP1271A (es)
AR (1) AR018177A1 (es)
AT (1) ATE303358T1 (es)
AU (1) AU752389B2 (es)
BG (1) BG104916A (es)
BR (1) BR9909486A (es)
CA (1) CA2327279A1 (es)
CO (1) CO5031246A1 (es)
DE (1) DE69927008T2 (es)
DZ (1) DZ2751A1 (es)
EA (1) EA200001039A1 (es)
EG (1) EG24178A (es)
ES (1) ES2247795T3 (es)
HU (1) HUP0101346A3 (es)
ID (1) ID27004A (es)
IL (1) IL138918A0 (es)
MX (1) MXPA00009844A (es)
MY (1) MY121054A (es)
NO (1) NO20005006L (es)
NZ (1) NZ507288A (es)
OA (1) OA11499A (es)
PE (1) PE20000415A1 (es)
PL (1) PL343357A1 (es)
SK (1) SK14852000A3 (es)
TR (1) TR200002896T2 (es)
UA (1) UA58586C2 (es)
WO (1) WO1999051569A1 (es)
ZA (1) ZA200005369B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180628A1 (es) * 1999-07-31 2002-07-30 Smithkline Beecham Corp Compuestos calcioliticos
MY159417A (en) * 2000-01-24 2017-01-13 Smithkline Beecham Corp Calcilytic compounds
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
AU2001277752A1 (en) 2000-08-11 2002-02-25 Japan Tobacco Inc. Calcium receptor antagonists
ATE343390T1 (de) * 2000-10-25 2006-11-15 Smithkline Beecham Corp Kalzilytische verbindungen
TWI316511B (en) * 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
SI1619180T1 (sl) 2003-04-23 2010-04-30 Japan Tobacco Inc Antagonist CaSR
EP1630157A4 (en) 2003-05-28 2007-05-23 Japan Tobacco Inc ANTAGONIST OF CASR
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US20070155819A1 (en) * 2004-02-06 2007-07-05 Marquis Robert W Jr Calcilytic compounds
US7648965B2 (en) * 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US20060293667A1 (en) * 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
AU2006285080B2 (en) 2005-09-02 2012-05-03 Amgen Inc. Methods of modulating intestinal fluid balance
WO2008121386A2 (en) * 2007-03-30 2008-10-09 Amgen Inc. Calcimimetic compounds for use in the treatment of bowel disorders
NZ593676A (en) * 2008-12-24 2012-06-29 Daiichi Sankyo Co Ltd Calcium-sensing receptor antagonists
WO2010103429A1 (en) 2009-03-10 2010-09-16 Pfizer Inc. 1,1-(Dimethyl-Ethylamino)-2-Hydroxy-Propoxy]-Ethyl}-3-Methyl-Biphenyl-4- Carboxylic Acid Derivatives As Calcium Receptor Antagonists
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
DE3301198A1 (de) * 1983-01-15 1984-07-19 Hoechst Ag, 6230 Frankfurt N-arylalkylamin-3-propoxypyridin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
ES2158996T3 (es) 1995-09-21 2001-09-16 Lilly Co Eli Agonistas beta3 adrenergicos selectivos.
ATE298739T1 (de) * 1996-04-09 2005-07-15 Nps Pharma Inc Calcylitische verbindungen

Also Published As

Publication number Publication date
NZ507288A (en) 2003-05-30
DZ2751A1 (fr) 2003-09-15
OA11499A (en) 2004-05-05
ATE303358T1 (de) 2005-09-15
ZA200005369B (en) 2001-12-18
HUP0101346A3 (en) 2003-03-28
AU752389B2 (en) 2002-09-19
JP2002510671A (ja) 2002-04-09
CO5031246A1 (es) 2001-04-27
EP1070048B1 (en) 2005-08-31
TR200002896T2 (tr) 2001-01-22
EP1070048A1 (en) 2001-01-24
NO20005006D0 (no) 2000-10-04
CA2327279A1 (en) 1999-10-14
MY121054A (en) 2005-12-30
KR20010042526A (ko) 2001-05-25
US6395919B1 (en) 2002-05-28
DE69927008D1 (de) 2005-10-06
DE69927008T2 (de) 2006-03-16
EG24178A (en) 2008-09-28
HUP0101346A2 (hu) 2001-08-28
AR018177A1 (es) 2001-10-31
PL343357A1 (en) 2001-08-13
ID27004A (id) 2001-02-22
CN1304401A (zh) 2001-07-18
SK14852000A3 (sk) 2001-05-10
HK1034243A1 (en) 2001-10-19
BG104916A (en) 2001-06-29
IL138918A0 (en) 2001-11-25
AU3481999A (en) 1999-10-25
EP1070048A4 (en) 2001-11-07
ES2247795T3 (es) 2006-03-01
AP1271A (en) 2004-04-21
AP2000001931A0 (en) 2000-09-30
BR9909486A (pt) 2001-11-06
WO1999051569A1 (en) 1999-10-14
EA200001039A1 (ru) 2001-04-23
UA58586C2 (uk) 2003-08-15
NO20005006L (no) 2000-10-04
MXPA00009844A (es) 2003-07-14

Similar Documents

Publication Publication Date Title
PE20000415A1 (es) Compuestos calciliticos
AR046411A1 (es) Derivados de bencimidazol. aplicaciones farmaceuticas
PE69299A1 (es) Compuestos calciliticos
PE20051039A1 (es) [1,8] naftiridin-2-onas y compuestos relacionados
ES2113081T3 (es) 1,4-benzotiazepinas utiles como agentes neurologicos.
EA200100798A1 (ru) Пиперидиновые, тетрагидропиридиновые и пиперазиновые производные, их получение и использование
DE60234092D1 (de) Agonisten und antagonisten von sphingosin-1-phosphatrezeptoren
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
ATE411985T1 (de) Substituierte piperazine als modulatoren des melanocortinrezeptors
MX9600484A (es) Anhidrato de clorhidrato de paroxetina y procedimiento para su preparacion.
BRPI0409109A (pt) novos compostos
DE60131967D1 (de) Nr1h4-kern-rezeptor-bindende verbindungen
PA8488101A1 (es) Moduladores de ccr5
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
BR9813284A (pt) Aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
AR049670A1 (es) Un derivado de acido aminometil carboxilico, su uso en el tratamiento de alteraciones del snc y una composicion farmaceutica que lo contiene
ATE435010T1 (de) Verwendung von retinoid rezeptor antagonisten für die behandlung von knochen und knorpel pathologien
ES2038172T3 (es) Procedimiento para preparar carboxamidas heterociclicas.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR0210285A (pt) Utilização de um composto, composto e composição farmacêutica
BRPI0721113A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios
PA8575001A1 (es) Fluorobenzamidas como inhibidores de maob
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
PE20040453A1 (es) Benzopiranonas halofenil y trifluorofenil sustituidas como moduladores de receptores de estrogeno

Legal Events

Date Code Title Description
FC Refusal